GSK Collaborates with CEPI to Develop Vaccine Against Corona Virus

 GSK Collaborates with CEPI to Develop Vaccine Against Corona Virus

GSK Collaborates with CEPI to Develop Vaccine Against Corona Virus

Shots:

  • GSK will utilize its adjuvant platform technology for developing a vaccine against the 2019-nCoV virus. The use of adjuvant technology lead to the production of more vaccine, thus increasing the availability to more people
  • GSK will engage with entities funded by the CEPI with the first of these agreements have been signed with Australia’s University of Queensland, which entered in an agreement with CEPI to develop a molecular clamp vaccine platform in Jan’2019
  • Both CEPI and GSK are committed to principles of equitable access and will work together to ensure that the principle governs the development, use, and access of 2019-nCoV vaccine developed via collaboration

Click here ­to­ read full press release/ article | Ref: GSK | Image: GSK

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post